Metagenomi Therapeutics
67 hedge funds and large institutions have $25.3M invested in Metagenomi Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 9 closing their positions.
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
120% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 10
24% more funds holding
Funds holding: 54 → 67 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.38% less ownership
Funds ownership: 32.54% → 31.16% (-1.4%)
49% less capital invested
Capital invested by funds: $49.6M → $25.3M (-$24.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$799K |
| 2 |
Renaissance Technologies
New York
|
+$632K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$603K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$547K |
| 5 |
Millennium Management
New York
|
+$363K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.38M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.22M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$1M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$992K |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$808K |
MGX Hedge Fund Activity: Q3 2024 in Review
67 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q3 2024, worth a combined $25.3M — down 49% from $49.6M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new MGX positions and 9 closed out — a net gain of 13 holders — while 22 added to existing stakes and 10 trimmed.
The largest buyer was Kestra Advisory Services, opening a new position worth an estimated $799K. The largest seller was Eventide Asset Management, exiting entirely with an estimated $2.38M sold.
- 67 institutional investors held Metagenomi Therapeutics (MGX) as of Q3 2024, up from 54 in Q2 2024.
- Funds reported $25.3M of Metagenomi Therapeutics stock for Q3 2024, down 49% quarter-over-quarter.
- 22 funds opened new Metagenomi Therapeutics positions in Q3 2024 and 9 closed out, a net change of +13 holders.
- The largest Metagenomi Therapeutics buyer in Q3 2024 was Kestra Advisory Services, an estimated $799K added.
- The largest Metagenomi Therapeutics seller in Q3 2024 was Eventide Asset Management, an estimated $2.38M sold.
Based on aggregated 13F filings for Q3 2024.